EuroPCR 2022 | Galileo Trial: Mortality Predictors after Successful TAVR

Patients undergoing TAVR are mostly older and more fragile, with comorbidities both cardiovascular and non-cardiovascular.  Therefore, they are associated with thromboembolic and bleeding risk.

Galileo Trial: Predictores de mortalidad luego del implante exitoso del TAVI

This study looked mortality predictors after successful TAVR in the Galileo trial

Mortality at 248 days was 9.2%, 5.5% being of cardiovascular cause and 3.9% non-cardiovascular. 

Mortality predictors were age >85, male sex, hemoglobin <10 g/dL, COPD, peripheral vascular disease, eGFR <45 ml/min/1,73m2 and functional class III-IV.

The presence of thromboembolic events was 8.5%, with time to event 151 days, stroke being the most frequent followed by MI and less frequently symptomatic valve thrombosis, TVP, pulmonary embolism and systemic embolism. 

BARC bleeding was 18.2%, with time to first bleeding of 66 days, BARC 3 being most frequent, followed by 2, and less frequently 1 and 5.

Death after thromboembolism according to Kaplan Meier curve, reached 54.4% within a 36-day event to death time. 

Read also: EuroPCR 2022 | ASTRO TAVR: Should we treat post TAVR Strokes with Neurointervention?

After BARC 2 or 3 bleeding, death was 17%, according to Kaplan Meier curve, within 178-day event to death time.

Bleedings BARC 2,3 and 5 were associated to mortality.

Authors have concluded that certain clinical variables are associated to mortality and that thromboembolic events are less frequent than bleeding, even though they are both associated to mortality (generally within a year). Moreover, they agree that the balance between bleeding event and thromboembolism after successful TAVR continues to be a challenge. 

Dr. Carlos Fava - Consejo Editorial SOLACI

Dr. Carlos Fava.
Member of the Editorial Board in SOLACI.org.


Subscribe to our weekly newsletter

Get the latest scientific articles on interventional cardiology

More articles by this author

Severe Tricuspid Regurgitation: Surgical vs. Transcatheter Edge-to-Edge Repair

While highly prevalent, tricuspid regurgitation is a notably undertreated valvulopathy. Its progression has been associated with higher mortality and significant disability. According to the...

ACCESS-TAVI: Comparing Post TAVR Vascular Closure Devices

Transcatheter aortic valve replacement (TAVR) is a well-established option to treat elderly patients with severe symptomatic aortic valve stenosis. Technical advances and device development...

Coronary Artery Disease in Aortic Stenosis: CABG + SAVR vs. TAVR + PCI: Data from Spanish Centers

Multiple randomized studies have shown comparable or superior efficacy of transcatheter aortic valve replacement (TAVR) vs. coronary artery bypass graft (CABG).  However, many of...

TCT 2024 | TRISCEND II: A New Hope in Percutaneous Tricuspid Valve Replacement

Advanced tricuspid regurgitation (TR) is a debilitating disease associated with heart failure and increased mortality.  Edge-to-edge repair has been shown to improve both clinical condition...

LEAVE A REPLY

Please enter your comment!
Please enter your name here

Related Articles

SOLACI Sessionsspot_img

Recent Articles

Severe Tricuspid Regurgitation: Surgical vs. Transcatheter Edge-to-Edge Repair

While highly prevalent, tricuspid regurgitation is a notably undertreated valvulopathy. Its progression has been associated with higher mortality and significant disability. According to the...

ACCESS-TAVI: Comparing Post TAVR Vascular Closure Devices

Transcatheter aortic valve replacement (TAVR) is a well-established option to treat elderly patients with severe symptomatic aortic valve stenosis. Technical advances and device development...

Endovascular Treatment of Iliofemoral Disease for the Improvement of Heart Failure with Preserved Ejection Fraction

Peripheral artery disease (PAD) is a significant risk factor in the development of difficult-to-treat conditions, such as heart failure with preserved ejection fraction (HFpEF)....